Efficacy and Safety of Inclisiran in Asian Patients: Results From ORION-18 (JACC Asia February 2024)-Article: Efficacy and Safety of Inclisiran in Asian Patients: Results From ORION-18

Article: Efficacy and Safety of Inclisiran in Asian Patients: Results From ORION-18

Pdf Summary

A study known as ORION-18 has evaluated the efficacy and safety of inclisiran in Asian patients with atherosclerotic cardiovascular disease (ASCVD) or a high risk of ASCVD. Inclisiran is a small interfering RNA (siRNA) that inhibits the synthesis of the proprotein convertase subtilisin/kexin type 9 (PCSK9) in hepatocytes. The study included 345 patients who were randomized to receive either inclisiran or a placebo. <br />The results showed that inclisiran was effective in reducing low-density lipoprotein cholesterol (LDL-C). The percentage reduction in LDL-C from baseline to day 330 was 57.2%, and the absolute reduction was 60.5 mg/dL. In addition, the study showed that inclisiran also reduced the levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) by 78.3%. Time-adjusted analyses also showed consistent LDL-C reduction with inclisiran. The incidence of adverse events with inclisiran was similar to that with the placebo. Overall, inclisiran was found to be effective and safe in Asian patients with ASCVD or a high risk of ASCVD. These findings confirm the clinical applicability of the results of global studies of inclisiran to Asian patients.

Keywords

ORION-18

efficacy

safety

inclisiran

Asian patients

atherosclerotic cardiovascular disease

LDL-C reduction

PCSK9 inhibition

placebo

clinical applicability